Dako has introduced IQISH technology, which aims to allow diagnosis of cancer in hours rather than days in determining the best treatment for the patient.
HER2 IQFISH pharmDx and TOP2A IQFISH pharmDx are the first two products available using the Dako IQISH technology, which enables laboratories to identify gene status with great accuracy as well as more quickly. With the IQFISH pharmDx kits, a FISH assay can be conducted in three and a half hours instead of the current two days. As an added benefit, the buffer is non-toxic, so the teratogenic risk of traditional formamide-containing FISH buffers can be avoided, providing a safer and healthier work environment for the laboratory technicians.
Both tests have received the CE-IVD label and are the first two IQISH products in Dako's Molecular Pathology portfolio. The products are available in in Europe from February.